These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22550269)

  • 1. Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice.
    Holmstock N; Annaert P; Augustijns P
    Drug Metab Dispos; 2012 Aug; 40(8):1473-7. PubMed ID: 22550269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption.
    Holmstock N; Mols R; Annaert P; Augustijns P
    Drug Metab Dispos; 2010 Sep; 38(9):1407-10. PubMed ID: 20551242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
    Tong L; Phan TK; Robinson KL; Babusis D; Strab R; Bhoopathy S; Hidalgo IJ; Rhodes GR; Ray AS
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3498-504. PubMed ID: 17664327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
    Hashiguchi Y; Hamada A; Shinohara T; Tsuchiya K; Jono H; Saito H
    Biochem Biophys Res Commun; 2013 Sep; 439(2):221-7. PubMed ID: 23981805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.
    Berginc K; Trdan T; Trontelj J; Kristl A
    Biopharm Drug Dispos; 2010 Nov; 31(8-9):495-505. PubMed ID: 21104925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
    Profit L; Eagling VA; Back DJ
    AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors.
    Iribarne C; Berthou F; Carlhant D; Dreano Y; Picart D; Lohezic F; Riche C
    Drug Metab Dispos; 1998 Mar; 26(3):257-60. PubMed ID: 9492389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring food effects on indinavir absorption with human intestinal fluids in the mouse intestine.
    Holmstock N; De Bruyn T; Bevernage J; Annaert P; Mols R; Tack J; Augustijns P
    Eur J Pharm Sci; 2013 Apr; 49(1):27-32. PubMed ID: 23402972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
    Huang L; Wring SA; Woolley JL; Brouwer KR; Serabjit-Singh C; Polli JW
    Drug Metab Dispos; 2001 May; 29(5):754-60. PubMed ID: 11302944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
    Wyen C; Fuhr U; Frank D; Aarnoutse RE; Klaassen T; Lazar A; Seeringer A; Doroshyenko O; Kirchheiner JC; Abdulrazik F; Schmeisser N; Lehmann C; Hein W; Schömig E; Burger DM; Fätkenheuer G; Jetter A
    Clin Pharmacol Ther; 2008 Jul; 84(1):75-82. PubMed ID: 18183034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
    Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
    Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
    Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
    Kuschak D; Mauss S; Schmutz G; Gantke B
    Clin Lab; 2001; 47(9-10):471-7. PubMed ID: 11596909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
    Kumar S; Kwei GY; Poon GK; Iliff SA; Wang Y; Chen Q; Franklin RB; Didolkar V; Wang RW; Yamazaki M; Chiu SH; Lin JH; Pearson PG; Baillie TA
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1161-71. PubMed ID: 12604693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials.
    Hill A; van der Lugt J; Sawyer W; Boffito M
    AIDS; 2009 Nov; 23(17):2237-45. PubMed ID: 19809270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
    van Heeswijk RP; Bourbeau M; Campbell P; Seguin I; Chauhan BM; Foster BC; Cameron DW
    J Clin Pharmacol; 2006 Jul; 46(7):758-67. PubMed ID: 16809801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of low-dose ritonavir in protease inhibitor combination therapy.
    Cooper CL; van Heeswijk RP; Gallicano K; Cameron DW
    Clin Infect Dis; 2003 Jun; 36(12):1585-92. PubMed ID: 12802760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
    Vernochet C; Azoulay S; Duval D; Guedj R; Ailhaud G; Dani C
    AIDS; 2003 Oct; 17(15):2177-80. PubMed ID: 14523274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of grapefruit juice and ritonavir on pharmacokinetics of lopinavir in Wistar rats.
    Ravi PR; Vats R; Thakur R; Srivani S; Aditya N
    Phytother Res; 2012 Oct; 26(10):1490-5. PubMed ID: 22308076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.